Cryofocus Medtech Shanghai Co. Ltd. has released its interim report for the first half of 2025, showing a significant increase in revenue. The company's revenue rose by RMB31.6 million, or 162.4%, from RMB19.5 million in the first six months of 2024 to RMB51.1 million for the same period in 2025. This growth was primarily driven by increased sales volume of respiratory intervention products, particularly the Malignant Stenosis Cryoablation System, which received approval from the NMPA in March 2025, and the Cryoadhesion System. The cost of sales also increased, rising from RMB4.2 million for the first half of 2024 to RMB16.8 million in 2025, in line with the growth in sales of commercialized products. Despite the rise in revenue, Cryofocus Medtech reported a decreased loss for the reporting period. The company's loss narrowed from RMB56.0 million in the first half of 2024 to RMB27.2 million for the same period in 2025. As of June 30, 2025, the company had total bank borrowings of RMB25.7 million with a fixed annual interest rate ranging from 3.45% to 3.50%. Capital expenditures during the period focused on expanding research and development facilities and enhancing manufacturing capacities. No specific outlook or guidance for future performance was provided in the report.